Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Hypermethylation of a New Distal Sodium/Iodide Symporter (NIS) Enhancer (NDE) Is Associated With Reduced NIS Expression in Thyroid Tumors

Full text
Author(s):
Galrao, Ana Luiza [1] ; Camargo, Rosalinda Y. [1] ; Friguglietti, Celso U. [2] ; Moraes, Lais [3] ; Cerutti, Janete Maria [3] ; Serrano-Nascimento, Caroline [4] ; Suzuki, Miriam F. [5] ; Medeiros-Neto, Geraldo [1] ; Rubio, Ileana G. S. [6]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, Sch Med FM USP, Cellular & Mol Endocrine Lab, Thyroid Unit, BR-01246903 Sao Paulo - Brazil
[2] Head & Neck Surg Santa Catarina Hosp, BR-01310000 Sao Paulo - Brazil
[3] Univ Fed Sao Paulo UNIFESP, Dept Morphol & Genet, Div Genet, Genet Bases Thyroid Tumors Lab, BR-04039032 Sao Paulo - Brazil
[4] Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, BR-05508900 Sao Paulo - Brazil
[5] IPEN CNEN SP, Inst Pesquisas Energet & Nucl, Ctr Biotechnol, BR-05508000 Sao Paulo - Brazil
[6] UNIFESP, Dept Biol Sci, BR-09972270 Diadema, SP - Brazil
Total Affiliations: 6
Document type: Journal article
Source: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM; v. 99, n. 6, p. E944-E952, JUN 2014.
Web of Science Citations: 12
Abstract

Context: In thyroid tumors, reduced radioiodine uptake is associated with worse patient outcome concomitantly with low sodium/iodide symporter (NIS) mRNA expression. Previous studies showed that CpG-island methylation in the NIS proximal promoter does not correlate with mRNA expression. Objectives: The aim of the study was to identify new CpG-islands within the NIS 5' region and investigate the involvement of their methylation in NIS expression. Design: DNA was obtained from 30 pairs of thyroid samples: tumor (T) and surrounding nontumor (NT) samples. All T samples had reduced NIS mRNA expression compared to NT samples. Main Outcome Measures: Methylation degree was quantified by bisulfite sequencing, and NIS expression by real-time PCR and Western blot. Reporter gene assays were performed to determine CpG-island functionality. Tumor cell cultures were treated with 5-Aza demethylating agent to determine NIS expression, methylation status, and I-125 uptake. Results: We identified a new CpG-island2 with 14 CpG sites, located -2152/-1887 relative to ATG site. CpG-island2 was hypermethylated in T compared to NT samples, in both benign and malignant tumor groups. There was a significant inverse correlation between NIS mRNA expression and degree of CpG-island2 methylation in NT and T samples. This sequence increased the expression of a reporter gene; thus, it was considered a new enhancer. Cell culture treatments with 5-Aza reduced CpG-island2 methylation levels concomitantly with restoration of NIS mRNA and protein expression and I-125 uptake. Conclusions: We identified a new distal enhancer, NIS distal enhancer, that regulates gene expression through DNA methylation. This enhancer is hypermethylated in T compared to NT samples and is associated with decreased NIS expression in tumors. This epigenetic deregulation may be an early event in tumorigenesis. (AU)

FAPESP's process: 09/52517-1 - Methylation of sodium iodide symporter (NIS) gene in thyroid tumors
Grantee:Ana Luiza Resende Galrão
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)